🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase I

Oncology programs at Phase I — ClinicalTrials.gov pipeline intelligence.

Programs
1,344

Quick answer

Oncology Phase I programs: NovaPharmaNews indexes 1,344 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 24 of 28

  1. Single agent of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer

    phase 1 small molecule active

    1 trial

  2. Single microdose trial - CXCR4 PET tracer - Pharmacokinetics and pharmacodynamics of [68Ga]Ga-R54, a CXCR4-targeted radiopharmaceutical in patients with advanced solid tumors.

    Fondazione Telethon ETS

    Advanced solid neoplasm (breast, lung, colon, ovary, pancreas) characterized by positive CXCR4 expression by immunohistochemistry

    phase 1 other active

    1 trial

  3. Study of Abemaciclib with Pembrolizumab in Patients with Stage IV Lung Cancer or Breast Cancer

    Eli Lilly Co.

    Lung Cancer or Breast Cancer

    phase 1 other active

    1 trial

  4. Study of DFF332 alone and in combination with Everolimus or Immuno-oncology therapies in patients with renal cell carcinoma and other selected tumors.

    Novartis Pharmaceuticals

    Advanced, relapsed Clear Cell Renal Cell Carcinoma

    phase 1 other active

    1 trial

  5. Study of EGF816 in combination with selected targeted agents in EGFR-mutant NSCLC.

    Novartis Pharmaceuticals

    Patients with EGFR-mutant Non Small Cell Lung Cancer

    phase 1 other active

    1 trial

  6. Study of GS-5319 in Adults With Solid Tumors

    Gilead Sciences Pty Limited

    Advanced solid tumors

    phase 1 other active

    1 trial

  7. Study of JNJ-74856665 in patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome

    Janssen-Cilag International N.V.

    Acute myeloid leukemia or Myelodysplastic syndrome

    phase 1 other active

    1 trial

  8. Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

    Merck Sharp and Dohme

    Advanced Pancreatic cancer, Unresectable Glioblastoma and Variants, PD-1-exposed Advanced/Met HNSCC, Advanced/Met HNSCC, Advanced/Met NSCLC, Advance/Met RCC, Advanced/Met Gastric or GEJ adenocarcinoma, Ovarian Cancer. TNBC, Advanced Mesothelioma, Advanced Solid tumors(coformulation)

    phase 1 other active

    1 trial

  9. Study of PIT565 in relapsed and/or refractory B-cell malignancies

    Novartis Pharmaceuticals

    Relapsed and/or refractory B-cell Non-Hodgkin lymphoma (R/R B-NHL) and relapsed and/or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL)

    phase 1 other active

    1 trial

  10. Study of REGN6569 and Cemiplimab in Adult Patients with Advanced Solid Tumor Malignancies

    Lacuna Pharma Pty Ltd

    Squamous Cell Carcinoma of Head and Neck

    phase 1 other active

    1 trial

  11. Study of Repotrectinib and CYP450 probe Cocktail in Patients with locally advanced or Metastatic Tyrosine Kinase Inhibitors (TKI)-Pretreated ROS1-Positive Non-small Cell Lung Cancer (NSCLC)

    Bristol-Myers Squibb Australia Pty Ltd

    Non-small Cell Lung Cancer (NSCLC)

    phase 1 other active

    1 trial

  12. Study of TSR-022, a Monoclonal Antibody, in Patients with Advanced Solid Tumors

    TESARO Bio Netherlands B.V.

    Patients with Advanced Solid Tumors

    phase 1 other active

    1 trial

  13. Study of U3-1402 in subjects with non-small cell lung cancer

    Daiichi Sankyo

    METASTATIC OR UNRESECTABLE NON-SMALL CELL LUNG CANCER

    phase 1 other active

    1 trial

  14. Study of safety and antitumor activity of GEN1056 in participants with advanced solid tumors

    Genmab A/S

    Advanced solid tumors

    phase 1 other active

    1 trial

  15. Study of safety and efficacy of DKY709 alone or in combination with PDR001 in patients with advanced solid tumors.

    Novartis Pharmaceuticals

    Nasopharyngeal Carcinoma, Triple Negative Breast Cancer, Microsatellite Stable Colorectal Cancer, Non-Small Cell Lung Cancer, Cutaneous Melanoma

    phase 1 other active

    1 trial

  16. Study of safety and preliminary efficacy of VAY736 given alone or in combination with other antineoplastic agents in patients with NHL

    Novartis Pharmaceuticals

    Relapsed/refractory Non Hodgkin Lymphoma

    phase 1 other active

    1 trial

  17. Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

    AbbVie Deutschland GmbH & Co. KG

    Non-Hodgkin's Lymphoma

    phase 1 other active

    1 trial

  18. Study to Evaluate the PK and Safety of Oral Decitabine and Cedazuridine in Cancer Patients with Hepatic Impairment

    Taiho Pharma Netherlands B.V.

    Solid tumor, Acute myeloid lymphoma (AML), Myelodysplastic syndrome (MDS)

    phase 1 other active

    1 trial

  19. Study to Evaluate the PK and Safety of Oral Decitabine and Cedazuridine in Cancer Patients with Renal Impairment

    Taiho Pharma Netherlands B.V.

    Acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), or solid tumors

    phase 1 other active

    1 trial

  20. Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

    Lacuna Pharma Pty Ltd

    B-cell non-Hodgkin lymphoma (NHL)

    phase 1 other active

    1 trial

  21. Study to evaluate the addition of an experimental drug, CC-90010, to the usual treatment of brain cancer after surgery

    Celgene Europe Limited

    Subjects with newly diagnosed WHO Grade IV glioblastoma (ndGBM) who have undergone complete or partial tumor resection

    phase 1 other active

    1 trial

  22. Study which tests 3 medicines (SB27, EU sourced Keytruda, and US sourced Keytruda) in early or locally advanced non-small cell lung cancer patients who underwent surgery and adjuvant chemotherapy

    Samsung Bioepis NL B.V.

    Non-small cell lung cancer

    phase 1 other active

    1 trial

  23. Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

    Amgen

    Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

    phase 1 other active

    1 trial

  24. Subcutaneous Trastuzumab Deruxtecan Phase 1 Trial.

    Daiichi Sankyo

    Advanced Solid Tumor

    phase 1 other active

    1 trial

  25. Sunitinib, Pemetrexed

    Pfizer

    Neoplasm, Malignant

    phase 1 small molecule completed

    1 trial

  26. Sup19 CAR-T

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B-Acute Lymphoblastic Leukemia

    phase 1 mab active

    1 trial

  27. T cell injection targeting CD7 chimeric antigen receptor

    The First People's Hospital of Lianyungang

    T Lymphoblastic Leukemia/Lymphoma

    phase 1 mab active

    1 trial

  28. TAEST16001

    Chongqing Precision Biotech Co., Ltd

    Liver Cancer Stage IV

    phase 1 small molecule completed

    1 trial

  29. TAEST16001 cells

    Chongqing Precision Biotech Co., Ltd

    Soft Tissue Sarcoma

    phase 1 mab active

    1 trial

  30. TAK-102

    Takeda

    Solid Tumors

    phase 1 mab terminated

    1 trial

  31. TAK-103

    Takeda

    Solid Tumors

    phase 1 mab terminated

    1 trial

  32. TAK-117

    Takeda

    Neoplasm, Advanced or Metastatic

    phase 1 small molecule completed

    1 trial

  33. TAK-117

    Takeda

    Metastatic Solid Tumors

    phase 1 small molecule completed

    1 trial

  34. TAK-164

    Takeda

    Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies

    phase 1 small molecule terminated

    1 trial

  35. TAK-165

    Takeda

    Breast Neoplasm

    phase 1 small molecule completed

    1 trial

  36. TAK-385

    Takeda

    Hormone Treatment-naïve Participants With Prostate Cancer

    phase 1 small molecule completed

    1 trial

  37. TAK-580

    Takeda

    Melanoma

    phase 1 small molecule terminated

    1 trial

  38. TAK-659

    Nektar Therapeutics UK Limited

    Lymphoma, Non-Hodgkin

    phase 1 small molecule terminated

    1 trial

  39. TAK-659

    Takeda

    Lymphoma, Non-Hodgkin

    phase 1 small molecule terminated

    1 trial

  40. TAK-676

    Takeda

    Head and Neck Squamous Cell Carcinoma

    phase 1 small molecule completed

    1 trial

  41. TAK-931

    Takeda

    Nonhematologic Neoplasms, Advanced

    phase 1 small molecule completed

    1 trial

  42. TAK-931 PIC

    Takeda

    Neoplasms, Advanced Solid

    phase 1 small molecule completed

    1 trial

  43. TAK-981

    Takeda

    Head and Neck Cancer

    phase 1 small molecule completed

    1 trial

  44. TALEN

    The First People's Hospital of Lianyungang

    Human Papillomavirus-Related Malignant Neoplasm

    phase 1 mab active

    1 trial

  45. TBio-6517

    Takeda

    Solid Tumor

    phase 1 mab terminated

    1 trial

  46. TCR-T cells

    The First People's Hospital of Lianyungang

    Recurrent Hepatocellular Carcinoma

    phase 1 mab active

    1 trial

  47. TEV-56278

    Teva Pharma GmbH

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  48. TG-1701

    TG THERAPEUTICS, INC.

    Non Hodgkin Lymphoma

    phase 1 small molecule terminated

    1 trial

Frequently asked questions

How many oncology Phase I programs exist?

1,344 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.